News - Page 3 of 7 - HanchorBio

HanchorBio Presents Early Frontline Triple-Negative Breast Cancer Data for HCB101 Combination at GBCC 2026

HanchorBio announced the first dedicated presentation of HCB101 clinical data from an ongoing study evaluating HCB101 in combination with anti-PD-1 and nab-paclitaxel in patients with advanced triple-negative breast cancer (TNBC) at the Global Breast Cancer Conference 2026 (GBCC 2026) in Seoul, Korea.

Apr 23, 2026

HanchorBio Reports Head and Neck Cancer Data for HCB101, Including Durable Monotherapy Activity and Complete Response at Low Dose in Combination with PD-1

HanchorBio reported updated clinical observations in head and neck squamous cell carcinoma (HNSCC) across both monotherapy and combination settings for HCB101, its rationally engineered SIRPα-Fc fusion protein functioning as an innate immune checkpoint blockade.

Apr 22, 2026

HanchorBio Reports Strong H1 2026 Scientific Communication Momentum and Highlights Upcoming Q2 Conference Participation

HanchorBio announced strong scientific communication momentum in the first half of 2026, marked by a broad series of oral, mini-oral, symposium, keynote, and poster presentations across major international scientific meetings. The Company also highlighted its upcoming and recently accepted conference participation in Q2 2026, underscoring continued external visibility across multiple programs, disease areas, and translational settings.

Apr 20, 2026

HanchorBio Announces Successful Completion of First 2,000L GMP Clinical Batch Production of HCB101

HanchorBio's HCB101, one of its core FBDB™ (Fc-Based Designer Biologics) oncology pipeline assets, has successfully completed its first GMP clinical batch production scaled up from a 500L to a 2,000L bioreactor. This production was carried out at WuXi Biologics’ manufacturing facility, covering the full process from Drug Substance (DS) to Drug Product (DP), and achieved all predefined manufacturing objectives.

Apr 14, 2026

HanchorBio Invited to Participate in the 19th QIC CEO Week

HanchorBio has been invited to participate in the 19th QIC CEO Week to meet with international institutional investors in Singapore to share corporate progress and strategic priorities.

Apr 13, 2026

HanchorBio Doses First Patient in Taiwan in Phase 1 Trial of HCB301

HanchorBio today announced that the first patient in Taiwan has been dosed in HCB301-101, the Company’s ongoing first-in-human Phase 1 clinical study of HCB301.

Apr 08, 2026

HanchorBio Signals “Backbone” Potential for HCB101 as SAB Aligns on Gastric Cancer Registrational Path

HanchorBio reported outcomes from its recent Scientific Advisory Board (SAB) meeting, highlighting a shift from platform validation to asset-level positioning and registrational strategy.

Apr 03, 2026

HanchorBio Reports Early Taiwan IIT Signal in 2L CRC With Sustained Disease Control Beyond 37 Weeks

HanchorBio today announced early findings from an ongoing investigator-initiated trial (IIT) in Taiwan evaluating HCB101-based combination therapy in patients with second-line colorectal cancer (CRC).

Apr 03, 2026

HanchorBio Reports Preliminary First-Line HER2+ Gastric Cancer Data for HCB101, Demonstrating 83.3% ORR

HanchorBio's early clinical observations show deep tumor reductions across dose levels, supporting continued development in combination settings.

Apr 01, 2026

HanchorBio Presents at WIC-APAC 2026: The CD47 Field Enters a New Design Era

HanchorBio participated in the World Immunotherapy Council Asia-Pacific Conference (WIC-APAC 2026), to be held on March 29, 2026, at the International Convention Center, Chang Yung-Fa Foundation, Taipei, Taiwan. At the conference, Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (CMO) of HanchorBio (Group), and CEO of HanchorBio US, was invited to present his clinical perspectives on CD47–SIRPα in cancer immunotherapy, as well as the latest trends in next-generation multi-checkpoint engineering.

Mar 30, 2026